A Phase IIa Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Safety and Efficacy of CNV1014802 in Patients With Trigeminal Neuralgia
Phase of Trial: Phase II
Latest Information Update: 26 Oct 2017
At a glance
- Drugs Vixotrigine (Primary)
- Indications Trigeminal neuralgia
- Focus Therapeutic Use
- Sponsors Convergence Pharmaceuticals
- 29 Oct 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 16 Jun 2014 Results published in the Convergence Pharmaceuticals Media Release.
- 28 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History